Preview

Клиницист

Расширенный поиск

Влияние блокаторов ренин-ангиотензин -альдостероновой системы на процессы ремоделирования миокарда и риск фибрилляции предсердий у больных артериальной гипертензией

https://doi.org/10.17650/1818-8338-2012-3-4-73-79

Полный текст:

Аннотация

В представленном обзоре рассматриваются механизмы, лежащие в основе развития и поддержания фибрилляции предсердий (ФП). Отмечено, что в основе структурных и функциональных изменений в предсердиях при ФП могут лежать процессы фиброза предсердий, ремоделирования ионных каналов, воспаления, апоптоза, нарушения межклеточных взаимодействий, гипертрофии клеток миокарда. Обоснована эффективность ингибиторов ангиотензинпревращающего фермента и антагонистов рецепторов ангиотензина у пациентов с систолической дисфункцией левого желудочка.

Об авторах

О. М. Драпкина
ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России
Россия
Кафедра пропедевтики внутренних болезней лечебного факультета


М. В. Костюкевич
ГБОУ ВПО «Первый МГМУ им. И.М. Сеченова» Минздрава России
Россия
Кафедра пропедевтики внутренних болезней лечебного факультета


Список литературы

1. Benjamin E.J., Wolf P.A., D'Agostino R.B. et al. Impact of Atrial Fibrillation on the Risk of Death: The Framingham Heart Study. Circulation 1998;98(10):946–52.

2. Go A.S., Hylek E.M., Phillips K.A. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285(18):2370–5.

3. Benjamin E.J., Levy D., Vaziri S.M. et al. Independent Risk Factors for Atrial Fibrillation in a Population-Based Cohort. The Framingham Heart Study. JAMA 1994;271(11):840–4.

4. D'Agostino R.B.Sr., Vasan R.S., Pencina M.J. et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117(6):743–53.

5. Kannel W.B., Abbott R.D., Savage D.D., McNamara P.M. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982;306(17):1018–22.

6. Bosch J., Yusuf S., Pogue J. et al. HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002;324(7339):699–702.

7. Psaty B.M., Manolio T.A., Kuller L.H. et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96(7):2455–61.

8. Verdecchia P., Reboldi G., Gattobigio R. et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41(2):218–23.

9. Hanna N., Cardin S., Leung T.K., Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004;63(2):236–44.

10. Li D., Fareh S., Leung T.K., Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation 1999;100(1):87–95.

11. Frohlich E.D., Tarazi R.C., Dustan H.P. Clinical-physiological correlations in the development of hypertensive heart disease. Circulation 1971;44(3):446–55.

12. Gerdts E., Oikarinen L., Palmieri V. et al.; Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.

13. Hypertension 2002;39(3):739–43.

14. Pearson A.C., Gudipati C., Nagelhout D. et al. Echocardiographic evaluation of cardiac structure and function in elderly subjects with isolated systolic hypertension. J Am Coll Cardiol 1991;17(2):422–30.

15. Okin P.M., Devereux R.B., Jern S. et al.; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292(19):2343–9.

16. Choisy S.C., Arberry L.A., Hancox J.C., James A.F. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension 2007;49(3):498–505.

17. Kistler P.M., Sanders P., Dodic M. et al. Atrial electrical and structural abnormalities in an ovine model of chronic blood pressure elevation after prenatal corticosteroid exposure: implications for development of atrial fibrillation. Eur Heart J 2006;27(24):3045–56.

18. Kostin S., Klein G., Szalay Z. et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002;54(2):361–79.

19. Anné W., Willems R., Roskams T. et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005;67(4):655–66.

20. Luo M.H., Li Y.S., Yang K.P. Fibrosis of collagen i and remodeling of connexin 43 in atrial myocardium of patients with atrial fibrillation. Cardiology 2006;107(4):248–53.

21. Ohtani K., Yutani C., Nagata S. et al. High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol 1995;25(5):1162–9.

22. Saito T., Tamura K., Uchida D. et al. Histopathological features of the resected left atrial appendage as predictors of recurrence after surgery for atrial fibrillation in valvular heart disease. Circ J 2007;71(1):70–8.

23. Kumagai K., Nakashima H., Urata H. et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003;41(12):2197–204.

24. Li D., Shinagawa K., Pang L. et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced

25. congestive heart failure. Circulation 2001;104(21):2608–14.

26. Sakabe M., Fujiki A., Nishida K. et al. Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and overexpression of connexin43 in a canine model of atrial pacinginduced left ventricular dysfunction. J Cardiovasc Pharmacol 2004;43(6):851–9.

27. Sakabe M., Shiroshita-Takeshita A., Maguy A. et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation

28. ;116(19):2101–09.

29. Shiroshita-Takeshita A., Brundel B.J., Burstein B. et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res 2007;74(1):75–84.

30. Tsai C.T., Lai L.P., Kuo K.T. et al. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008;117(3):344–55.

31. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31(19):2369–429.

32. Goette A., Arndt M., Röcken C. et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000;101(23):2678–81.

33. Goette A., Staack T., Röcken C. et al. Increased expression of extracellular signalregulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35(6):1669–77.

34. Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90(4):2056–69.

35. Urata H., Boehm K.D., Philip A. et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993;91(4):1269–81.

36. Wei C.C., Hase N., Inoue Y. et al. Mast cell chymase limits the cardiac efficacy of Ang I–converting enzyme inhibitor. J Clin Invest 2010;120(4):1229–39.

37. Nakashima H., Kumagai K., Urata H. et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101(22):2612–7.

38. Wachtell K., Hornestam B., Lehto M. et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45(5):705–11.

39. Devereux R.B., Dahlöf B., Gerdts E. et al. Regression of Hypertensive Left Ventricular Hypertrophy by Losartan Compared With Atenolol The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Trial. Circulation 2004;110(11):1456–62.

40. Ibsen H., Lindholm L.H., Pedersen O.L. et al. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFEstudy (in Danish). Ugeskr Laeger 2003;165(5):459–62.

41. Ibsen H., Wachtell K., Olsen M.H.; LIFE Substudy. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension and left ventricular hypertrophy? A LIFE

42. Substudy. J Hypertens 2004;22(9):1805–11.

43. Brown N.J., Kumar S., Painter C.A., Vaughan D.E. ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism: Differential Effects on PAI-1 Over Time. Hypertension 2002;40(6);859–65.

44. Khan N., McAlister F.A. Re-examining the efficacy of β-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174(12):1737–42.

45. Cohen-Solal A., McMurray J.J., Swedberg K. et al.; CHARM Investigators. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. Eur Heart J 2008;29(24):3022–8. 42. Hansson L., Lindholm L.H., Niskanen L. et al. Effect of angiotensinconverting-

46. enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353(9153):611–6.

47. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–97.

48. ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547–59.

49. Healey J.S., Baranchuk A., Crystal E. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis. J Am Coll Cardiol

50. ;45(11):1832–9.

51. Schneider M.P., Hua T.A., Bohm M. et al. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a metaanalysis. J Am Coll Cardiol 2010;55(21):2299–307.


Для цитирования:


Драпкина О.М., Костюкевич М.В. Влияние блокаторов ренин-ангиотензин -альдостероновой системы на процессы ремоделирования миокарда и риск фибрилляции предсердий у больных артериальной гипертензией. Клиницист. 2012;6(3-4):73-79. https://doi.org/10.17650/1818-8338-2012-3-4-73-79

For citation:


Drapkina O.M., Kostyukevich M.V. Effect of renin-angiotensin -aldosterone system blockers on myocardial remodeling processes and risk for atrial fibrillation in patients with arterial hypertension. The Clinician. 2012;6(3-4):73-79. (In Russ.) https://doi.org/10.17650/1818-8338-2012-3-4-73-79

Просмотров: 320


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1818-8338 (Print)
ISSN 2412-8775 (Online)